Loading
You cannot study a cancer without a laboratory model of it, and most rare cancers have none. A funded bank that makes and shares models would unlock research.
Rare tumour research stalls because there is no cell line, organoid or xenograft to work with, and individual laboratories cannot justify the cost of derivation for a disease they may study once. A central derivation facility taking fresh surgical material from a referral network, generating organoids and xenografts, characterising them and distributing them openly on a cost-recovery basis would remove the barrier for hundreds of diseases at once.
Shares Cancer Models (PDCM Finder) & HCMI, Patient-derived xenografts, Functional (ex vivo) drug testing, Patient-derived organoids.
Shares Rare cancers are not so rare: the rare cancer burden in Europe, Patient-derived xenografts, Functional (ex vivo) drug testing, Patient-derived organoids.
Shares Cancer Models (PDCM Finder) & HCMI, DepMap (Cancer Dependency Map), Patient-derived xenografts, Patient-derived organoids.
Shares Rare cancers are not so rare: the rare cancer burden in Europe, Mesothelioma, Rare and paediatric cancers without markets, Neuroendocrine tumours.
Shares Patient-derived xenografts, Patient-derived organoids, Lab models that fail to predict what happens in patients, Rare and paediatric cancers without markets.
Shares Cancer Models (PDCM Finder) & HCMI, DepMap (Cancer Dependency Map), Functional (ex vivo) drug testing, Patient-derived organoids.
Shares Mesothelioma, Rare and paediatric cancers without markets, Neuroendocrine tumours, Sarcomas (soft tissue, bone, GIST).
Shares DepMap (Cancer Dependency Map), Functional (ex vivo) drug testing, Patient-derived organoids, Lab models that fail to predict what happens in patients.